The FDA's decision was based on data from the Phase 3 PARADIGMS study (N=215) which evaluated the safety and efficacy of oral fingolimod vs interferon beta-1a injection in pediatric patients aged 10 to <18 years with relapsing MS.
Investigators designed a parallel-group, 2-arm, randomized controlled trial to evaluate ELEVIDA, an online fatigue management program based on cognitive behavioral therapy and other therapy-based strategies.
Previous studies have shown that delayed-release DMF is safe and effective in treating RRMS in adult patients. The goal of this study was to extend these analyses to evaluate DMF in pediatric patients with RRMS.
Cases of acalculous cholecystitis and a single case of acute coronary syndrome associated with the use of alemtuzumab are reported.
A regression model showed that efficacy of DMTs significantly decreased until age 53, after which disease progression is not affected by DMTs.
Researchers sought to compare the safety and efficacy of ozanimod vs interferon β-1a in individuals with relapsing multiple sclerosis.
Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying TherapyApril 23, 2018
The new guidelines focus on helping clinicians decide when to initiate, switch, or discontinue disease-modifying therapies for multiple sclerosis.
Researchers found there are no associations between vaccinations and multiple sclerosis relapse flares.
Researchers investigated the association between cardiovascular risk factors and the development of brain atrophy in individuals with multiple sclerosis.
A cross-sectional study aimed to assess the effect of smoking and alcohol consumption along with the interactions they have on the clinical course of multiple sclerosis.
As injectable disease-modifying therapies can be inconvenient for patients with MS, fingolimod offers an oral treatment option that is associated with significantly lower risk for relapse.
Compared with consuming fish less than once per month and no supplements, high fish intake was correlated with a significantly reduced risk of multiple sclerosis.
Participants who were treated with both doses of fingolimod experienced less overall progression of disability than those receiving placebo.
Of the total patients, 178 (29.7%) discontinued DMT during the study period with only 1 documented relapse occurring in the discontinuers.
Further research should focus on establishing whether siponimod exerts its effect on the pathogenic processes associated with disease progression or activity, or both.
The study was unable to verify whether the findings may be applicable for lesion locations other than those found with brain biopsies.
The effect of 8 weeks of combined exercise training on serum BDNF concentration was examined in patients with relapsing-remitting multiple sclerosis.
A cohort study evaluated the effects of smoking on disease activity in interferon beta-treated relapsing-remitting multiple sclerosis.
The impact of treatment with dimethyl fumarate and fingolimod on lymphocyte and leukocyte count was evaluated in patients with multiple sclerosis.
Risk of multiple sclerosis may be reduced with high sun exposure.
Daclizumab, an interleukin-2 (IL-2) receptor blocking antibody, was approved in May 2016 to treat adults with relapsing forms of MS.
Glatopa 40 mg has been launched for the treatment of relapsing multiple sclerosis.
Natalizumab exposure is associated with an increased risk of spontaneous abortion for pregnant women with multiple sclerosis.
Intakes of fats and types of fatty acids may affect disability severity in multiple sclerosis and neuromyelitis optica spectrum disorder.
Patients with multiple sclerosis who were motivated to remain adherent to treatment experienced overall better outcomes, including low relapse rates.
Barriers to using screening tools included lack of time and lack of insurance compensation.
Data obtained from the iConquerMS network highlight areas of quality of life that affect people with relapsing and progressive forms of MS and provide substantial basis for future research.
Vitamin D deficiency is a risk factor for multiple sclerosis.
The association suggests that caffeine consumption may play a protective role against multiple sclerosis-related disability.
Poor medication timing, incorrect doses, medication disorganization, and under- or over-medication are some of the medication adherence issues that can occur in patients with MS and cognitive symptoms.
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Psychological Therapies May Help Older Adults With Chronic Pain
- FDA Approves First Multiple Sclerosis Treatment for Pediatric Patients
- Concussion Misdiagnosis Associated With Emergency Department Stay, Injury Type
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- Micronutrient Levels May Be Altered in ADHD
- Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy
- Solriamfetol Associated With Improvement in Narcolepsy Types 1 and 2
- FDA Approves Aimovig for Migraine Prevention
- FDA: Lamotrigine Linked to Potentially Life-Threatening Adverse Reaction
- Evolution of NEDA: Q&A With Cleveland Clinic's Dr Robert Bermel
- Inactivity, Obesity Exert No Significant Influence on Parkinson Disease Risk
- White House Unveils Plan to Lower Cost of Prescription Drugs
- Tenecteplase Improves Reperfusion and Functional Outcome in Ischemic Stroke
- Briviact Approved for Pediatric Patients With Partial-Onset Seizures